Russian Antineoplastic Drug Approved by WHO!
Varisacumab is an international non-proprietary name (INN) adopted by the World Health Organization (WHO) for antineoplastic Russian drug Apagin.
Varisacumab has been developed and is manufactured by Generium. It is a human monoclonal antibody obtained using technologies of recombinant DNA. Apagin is selectively bound with vascular endothelial growth factor (VEGF), preventing its interaction with type two VEGF receptor, leading to inhibition of vascular growth, decreased vascularization and tumor growth inhibition.
Currently work on selection of optimal doses and determination of effects and safety of Apagin in combination with standard chemotherapy in patients with metastatic colorectal cancer (phase II-III). To that purpose a multicenter international prospective randomized placebo-controlled double-blind parallel-group clinical trial is ongoing, and is about to be completed..